Unnamed: 0,title,date,stock,sentiment
493359.0,FibroGen Announces New Roxadustat Data Presented At 2020 ERA-EDTA Virtual Congress,2020-06-08 17:01:00-04:00,FGEN,neutral
493360.0,FibroGen Announces First Patient Enrolled In Pamrevlumab Clinical Trial In Patients Hospitalized In Italy With Severe COVID-19,2020-06-08 07:02:00-04:00,FGEN,negative
493361.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,FGEN,neutral
493362.0,Astellas Pharma And FibroGen Announce European Medicines Agency Accepts Astellas' Marketing Authorization Application For Roxadustat,2020-05-21 07:08:00-04:00,FGEN,positive
493363.0,"SVB Leerink Maintains Outperform on FibroGen, Lowers Price Target to $80",2020-05-08 12:59:00-04:00,FGEN,negative
493364.0,"FibroGen Q1 EPS $(0.890) Down From $(0.530) YoY, Sales $24.401M Up From $23.863M YoY",2020-05-07 16:32:00-04:00,FGEN,neutral
493365.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,FGEN,negative
493366.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,FGEN,neutral
493367.0,"Benzinga's Top Upgrades, Downgrades For May 1, 2020",2020-05-01 09:40:00-04:00,FGEN,positive
493368.0,"Cowen & Co. Initiates Coverage On FibroGen with Market Perform Rating, Announces Price Target to $40",2020-05-01 06:38:00-04:00,FGEN,neutral
493369.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2020",2020-04-27 09:32:00-04:00,FGEN,positive
493370.0,"B of A Securities Initiates Coverage On FibroGen with Neutral Rating, Announces Price Target to $45",2020-04-27 07:08:00-04:00,FGEN,positive
493371.0,FibroGen Announces UK Has Held Certain Patents Relating To 'methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors' To Be Invalid; Ruling Does Not Affect Validity Of Patents In Rest Of Europe,2020-04-20 07:09:00-04:00,FGEN,neutral
493372.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,FGEN,negative
493373.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,FGEN,negative
493374.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,FGEN,negative
493375.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,FGEN,negative
493376.0,"FibroGen Q4 EPS $(1.12) Misses $(0.59) Estimate, Sales $7.974M Down From $108.054M YoY",2020-03-02 16:03:00-05:00,FGEN,negative
493377.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,FGEN,neutral
493378.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,FGEN,positive
493379.0,FibroGen Reports FDA Accepted New Drug Application for Roxadustat For Treatment Of Anemia Of Chronic Kidney Disease,2020-02-11 17:04:00-05:00,FGEN,positive
493380.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,FGEN,positive
493381.0,7 Blockbuster Drugs Expected To Be Launched In 2020,2020-01-20 14:18:00-05:00,FGEN,positive
493382.0,FibroGen Announces Enrique Conterno CEO,2020-01-06 07:03:00-05:00,FGEN,neutral
493383.0,FibroGen Submits New Drug Application for Roxadustat in Patients With Anemia of Chronic Kidney Disease,2019-12-23 07:06:00-05:00,FGEN,neutral
493384.0,FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List,2019-12-02 07:03:00-05:00,FGEN,neutral
493385.0,Fibrogen shares are trading higher after Roxadustat was added to a national insurance list for coverage by China's state-run medical insurance fund.,2019-11-29 10:24:00-05:00,FGEN,positive
493386.0,"Fibrogen Shares Fall To Session Low, Down 4%; Muddy Waters Research Tweets 'Under-reported deaths in clinical trial - this looks pretty serious (no position)'",2019-11-12 12:59:00-05:00,FGEN,positive
493387.0,58 Biggest Movers From Yesterday,2019-11-12 04:25:00-05:00,FGEN,neutral
493388.0,FibroGen shares are trading lower after the company reported worse-than-expected Q3 EPS results.,2019-11-11 16:05:00-05:00,FGEN,neutral
493389.0,"FibroGen Q3 EPS $(0.57) Misses $(0.55) Estimate, Sales $33.17M Beat $31.6M Estimate",2019-11-11 16:02:00-05:00,FGEN,negative
493390.0,These Are The Winners Of The Inaugural WeTrader Paper Trading Competition,2019-11-11 10:53:00-05:00,FGEN,positive
493391.0,"Earnings Scheduled For November 11, 2019",2019-11-11 03:44:00-05:00,FGEN,neutral
493392.0,FibroGen Shares Resume Trade,2019-11-08 14:33:00-05:00,FGEN,positive
493393.0,FibroGen Shares To Resume Trade At 2:30 p.m. ET,2019-11-08 14:13:00-05:00,FGEN,positive
493394.0,AstraZeneca Says Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy And No Increased Cardiovascular Risk In Patients With Anemia From Chronic Kidney Disease Versus Comparators,2019-11-08 14:04:00-05:00,FGEN,positive
493395.0,"FibroGen Shares Halted, News Pending",2019-11-08 13:57:00-05:00,FGEN,positive
493396.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,FGEN,neutral
493397.0,FibroGen Presents Phase 3 Efficacy And Safety Results For Roxadustat Versus Epoetin Alfa As Treatment Of Anemia In Incident Dialysis Patients With Chronic Kidney Disease,2019-11-07 17:16:00-05:00,FGEN,positive
493398.0,46 Biggest Movers From Yesterday,2019-11-05 04:45:00-05:00,FGEN,neutral
493399.0,35 Stocks Moving In Monday's Mid-Day Session,2019-11-04 13:37:00-05:00,FGEN,neutral
493400.0,UPDATE: Plainview Says We are short $FGEN and believe $FGEN's ASN 2019 pres on Fri Nov 8 will show lead drug roxadustat failed to achieve key endpt of MACE non-inferiority in DD-CKD/NDD-CKD',2019-11-04 09:35:00-05:00,FGEN,negative
493401.0,Plainview Out With Short Report On FibroGen,2019-11-04 09:33:00-05:00,FGEN,neutral
493402.0,FibroGen Announces First Patient Dosed In LAPIS Phase 3 Clinical Trial Of Pamrevlumab For The Treatment Of Patients With Locally Advanced Pancreatic Cancer,2019-10-23 07:22:00-04:00,FGEN,negative
493403.0,Fibrogen Reports Initiation of Phase 2 Trial Of Roxadustat For Patients With Anemia In Cancer After Reciving Chemotherapy,2019-09-26 07:07:00-04:00,FGEN,negative
493404.0,"The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering",2019-09-20 07:46:00-04:00,FGEN,positive
493405.0,Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients,2019-09-20 03:49:00-04:00,FGEN,positive
493406.0,Jon Najarian Sees Unusual Options Activity In Freeport-McMoRan And FibroGen,2019-08-27 07:12:00-04:00,FGEN,neutral
493407.0,"Mizuho Maintains Buy on FibroGen, Maintains $65 Price Target",2019-08-26 12:44:00-04:00,FGEN,neutral
493408.0,FibroGen Option Alert: Jan 17 $45 Calls at the Ask: 3950 @ $5.6 vs 50 OI; Ref=$43.025,2019-08-26 11:05:00-04:00,FGEN,positive
493409.0,FibroGen Option Alert: Jan 17 $45 Calls Sweep (2) near the Ask: 4000 @ $5.6 vs 50 OI; Ref=$43.1,2019-08-26 10:49:00-04:00,FGEN,positive
493410.0,"FibroGen Announces the Death of its CEO, James Schoeneck Named Interim CEO",2019-08-26 08:35:00-04:00,FGEN,negative
493411.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,FGEN,positive
493412.0,FibroGen's Roxadustat Approved In China For Treatment Of Anemia In Chronic Kidney Disease Patients Not Receiving Dialysis,2019-08-21 16:16:00-04:00,FGEN,positive
493413.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,FGEN,positive
493414.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,FGEN,negative
493415.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,FGEN,neutral
493416.0,52 Stocks Moving In Friday's Pre-Market Session,2019-08-09 08:30:00-04:00,FGEN,neutral
493417.0,"FibroGen Q2 EPS $1.26 Beats $(0.51) Estimate, Sales $191.566M Beat $29.03M Estimate",2019-08-08 16:46:00-04:00,FGEN,neutral
493418.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,FGEN,neutral
493419.0,FibroGen Announces First Patient Dosed In ZEPHYRUS Phase 3 Clinical Trial Of Pamrevlumab For Treatment Of Patients With Idiopathic Pulmonary Fibrosis,2019-07-22 07:21:00-04:00,FGEN,neutral
493420.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,FGEN,positive
493421.0,The Week Ahead In Biotech: Pending Clinical Readouts In Focus,2019-06-29 08:25:00-04:00,FGEN,neutral
493422.0,"FibroGen To Present Interim Phase 2 Data On Pamrevlumab In Subjects With Duchenne Muscular Dystrophy At Parent Project Muscular Dystophy Conference Fri., Jun. 28, 2019",2019-06-28 07:02:00-04:00,FGEN,neutral
493423.0,"Goldman Sachs Assumes FibroGen at Neutral, Announces Price Target $45",2019-05-29 08:02:00-04:00,FGEN,neutral
493424.0,72 Biggest Movers From Friday,2019-05-13 05:09:00-04:00,FGEN,neutral
493425.0,62 Stocks Moving In Friday's Mid-Day Session,2019-05-10 12:35:00-04:00,FGEN,neutral
493426.0,"FibroGen shares are trading lower following results from a study of roxadustat. A STAT News article suggested the company's ""obtuse disclosure"" raised concerns about heart safety with the candidate.",2019-05-10 09:17:00-04:00,FGEN,positive
493427.0,25 Stocks Moving In Friday's Pre-Market Session,2019-05-10 08:35:00-04:00,FGEN,neutral
493428.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,FGEN,negative
493429.0,"'Fibrogen's obtuse disclosures about anemia pill raise concerns about heart safety, putting approval at risk' -STAT News",2019-05-10 07:56:00-04:00,FGEN,positive
493430.0,"William Blair Downgrades FibroGen, Inc - Common Stock to Market Perform",2019-05-10 06:58:00-04:00,FGEN,neutral
493431.0,"FibroGen Q1 EPS $(0.53) Beats $(0.67) Estimate, Sales $23.863M Beat $17.88M Estimate",2019-05-09 17:44:00-04:00,FGEN,neutral
493432.0,FibroGen Announces 'Positive' Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program,2019-05-09 17:42:00-04:00,FGEN,positive
493433.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,FGEN,neutral
493434.0,FibroGen Receives Orphan Drug Designation from the US FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy,2019-04-15 07:03:00-04:00,FGEN,neutral
493435.0,"Benzinga's Top Upgrades, Downgrades For April 12, 2019",2019-04-12 09:31:00-04:00,FGEN,positive
493436.0,"PiperJaffray Initiates Coverage On FibroGen with Neutral Rating, Announces $65 Price Target",2019-04-12 07:19:00-04:00,FGEN,neutral
493437.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-23 12:20:00-04:00,FGEN,neutral
493438.0,"FibroGen Q4 EPS $0.23, Sales $108.05M Beat $72.15M Estimate",2019-02-27 16:58:00-05:00,FGEN,neutral
493439.0,"FibroGen Q4 EPS $0.23 Beats $(0.10) Estimate, Sales $108.05M Beat $72.15M Estimate",2019-02-27 16:12:00-05:00,FGEN,neutral
493440.0,"Stifel Nicolaus Reinstates Buy on FibroGen, Announces $71 Target",2019-02-11 06:37:00-05:00,FGEN,neutral
493441.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,FGEN,neutral
493442.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,FGEN,neutral
493443.0,46 Stocks Moving In Thursday's Mid-Day Session,2018-12-20 12:37:00-05:00,FGEN,neutral
493444.0,FibroGen shares are trading up 7.5% after the company announced all three Phase 3 Roxadustat trials met primary efficacy endpoints.,2018-12-20 09:55:00-05:00,FGEN,positive
493445.0,FibroGen Announces All Three Phase 3 Trials Of Roxadustat For Chronic Kidney Disease Met Primary Efficacy Endpoints,2018-12-20 09:48:00-05:00,FGEN,neutral
493446.0,FibroGen shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and announced a price target of $71.,2018-12-19 15:24:00-05:00,FGEN,positive
493447.0,44 Stocks Moving In Wednesday's Mid-Day Session,2018-12-19 12:40:00-05:00,FGEN,neutral
493448.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2018",2018-12-19 09:11:00-05:00,FGEN,positive
493449.0,"Citigroup Upgrades FibroGen to Buy, Announces $71 Price Target",2018-12-19 07:29:00-05:00,FGEN,neutral
493450.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-12-18 12:29:00-05:00,FGEN,neutral
493451.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-12-18 08:41:00-05:00,FGEN,neutral
493452.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,FGEN,positive
493453.0,FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis,2018-12-17 20:57:00-05:00,FGEN,positive
493454.0,FibroGen Option Alert: Mar 15 $45 Calls Sweep (31) near the Ask: 558 @ $5.281 vs 126 OI; Ref=$40.0,2018-12-14 13:46:00-05:00,FGEN,positive
493455.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,FGEN,negative
493456.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018",2018-11-20 09:12:00-05:00,FGEN,negative
493457.0,"FibroGen Q3 EPS $(0.50) Down From $(0.32) YoY, Sales $29.03M Down From $40.55M YoY",2018-11-08 16:04:00-05:00,FGEN,neutral
493458.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,FGEN,negative
493459.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,FGEN,negative
493460.0,FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at ASN Kidney Week 2018 Annual Meeting,2018-10-26 04:20:00-04:00,FGEN,neutral
493461.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,FGEN,negative
493462.0,"Astellas Pharma, FibroGen Report Astellas Submitted New Drug Application For Marketing Approval In Japan Of Roxadustat For Treatment Of Anemia Associated With Chronic Kidney Disease In Patients On Dialysis",2018-10-01 08:02:00-04:00,FGEN,positive
493463.0,Fibrogen 8-K Shows Co. Received Fast Track Designation For Pamrevlumab For Treatment Of Idiopathic Pulmonary Fibrosis,2018-09-12 09:29:00-04:00,FGEN,neutral
493464.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,FGEN,positive
493465.0,"FibroGen Q2 EPS $(0.28) May Not Compare To $(0.59) Estimate, Sales $43.95M May Not Compare To $27.74M Estimate",2018-08-07 16:54:00-04:00,FGEN,neutral
493466.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,FGEN,negative
493467.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,FGEN,neutral
493468.0,"Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap",2018-06-22 08:51:00-04:00,FGEN,neutral
493469.0,FibroGen Announces Completion Of Enrollment In U.S. Phase 3 Clinical Program For Roxadustat In Anemia Associated With Chronic Kidney Disease,2018-06-07 07:01:00-04:00,FGEN,neutral
493470.0,FibroGen Presents Positive Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at #ASCO2018,2018-06-04 04:19:00-04:00,FGEN,positive
493471.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,FGEN,negative
493472.0,FibroGen Announces PRIASE Phase 2b Study Data Presented At American Thoracic Society 2018 Event,2018-05-21 16:04:00-04:00,FGEN,neutral
493473.0,FibroGen Upgraded By Mizuho On Continued R&D Progress,2018-05-15 17:29:00-04:00,FGEN,positive
493474.0,"Benzinga's Top Upgrades, Downgrades For May 15, 2018",2018-05-15 10:45:00-04:00,FGEN,positive
493475.0,Mizuho Upgrades FibroGen to Buy,2018-05-15 06:07:00-04:00,FGEN,neutral
493476.0,"FibroGen Q1 EPS $(0.50) Beats $(0.51) Estimate, Sales $31.925M Beat $27.15M Estimate",2018-05-09 17:08:00-04:00,FGEN,neutral
493477.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,FGEN,neutral
493478.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,FGEN,neutral
493479.0,Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab,2018-03-01 07:02:00-05:00,FGEN,positive
493480.0,"FibroGen Reports Q4 EPS $(0.27) vs $(0.29) Est., Sales $42.509M vs $49.8M Est.",2018-02-27 17:16:00-05:00,FGEN,neutral
493481.0,FibroGen Q4 Earnings Outlook,2018-02-27 12:53:00-05:00,FGEN,neutral
493482.0,"FibroGen Reports Q3 EPS $(0.50) vs. $(0.38) In Same Qtr. Last Year, Sales $27.3M vs. $30.1M YoY",2017-11-08 16:05:00-05:00,FGEN,neutral
493483.0,UPDATE: FibroGen Reports NDA Submission Triggers $15M Milestone Payment To FibroGen By AstraZeneca,2017-10-18 07:03:00-04:00,FGEN,neutral
493484.0,FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application,2017-10-18 07:01:00-04:00,FGEN,positive
493485.0,"The Week Ahead: Earnings, Earnings, And More Earnings",2017-10-16 10:49:00-04:00,FGEN,neutral
493486.0,"Secondary Offering Lockup Expirations Today for Performance Food Group, Fibrogen, and AZUL",2017-10-16 09:47:00-04:00,FGEN,neutral
493487.0,"Lightning Round: Jim Cramer Gives His Opinion On Kratos Defense & Security Solutions, Nike And More",2017-10-11 08:43:00-04:00,FGEN,positive
493488.0,20 Biggest Mid-Day Losers For Thursday,2017-10-05 12:52:00-04:00,FGEN,negative
493489.0,"Benzinga's Top Upgrades, Downgrades For October 5, 2017",2017-10-05 09:26:00-04:00,FGEN,positive
493490.0,"Mizuho Initiates Coverage On FibroGen with Neutral Rating, Announces $61.00 Price Target",2017-10-05 06:55:00-04:00,FGEN,neutral
493491.0,Fibrogen Phase 2b Study of Pamrevlumab Met Primary Endpoint,2017-09-13 07:12:00-04:00,FGEN,neutral
493492.0,FibroGen Prices 8M Share Offering @$40.75/Share,2017-08-16 03:53:00-04:00,FGEN,positive
493493.0,FibroGen Announces $300M Follow-On Offering Common Stock,2017-08-14 16:30:00-04:00,FGEN,neutral
493494.0,Fibrogen Files to Sell Up to $300M of Common Stock,2017-08-14 16:27:00-04:00,FGEN,neutral
493495.0,Morgan Stanley Expects Galapagos Shares To Rise 10%,2017-08-10 11:36:00-04:00,FGEN,positive
493496.0,Mid-Afternoon Market Update: Michael Kors Gains On Earnings Beat; Commercial Vehicle Shares Slide,2017-08-08 14:30:00-04:00,FGEN,positive
493497.0,18 Biggest Mid-Day Gainers For Tuesday,2017-08-08 12:34:00-04:00,FGEN,neutral
493498.0,Mid-Day Market Update: Stocks Turn Higher; Depomed Shares Plummet,2017-08-08 12:06:00-04:00,FGEN,positive
493499.0,Mid-Morning Market Update: Markets Edge Lower; CVS Health Profit Tops Expectations,2017-08-08 10:13:00-04:00,FGEN,positive
493500.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-08-08 08:06:00-04:00,FGEN,neutral
493501.0,"FibroGen Reports Q2 Loss/Share $(0.48) vs. $(0.47) Est., Sales $29M vs. $34.32M Est.",2017-08-07 16:50:00-04:00,FGEN,neutral
493502.0,Goldman Sachs Downgrades FibroGen to Neutral,2017-07-21 07:17:00-04:00,FGEN,neutral
493503.0,"Jefferies Initiates Coverage On FibroGen with Buy Rating, Announces $50.00 Price Target",2017-07-11 07:43:00-04:00,FGEN,neutral
493504.0,FibroGen Granted FDA Orphan Drug Designation for Pamrevlumab in Treatment of Pancreatic Cancer GLN,2017-06-22 04:52:00-04:00,FGEN,negative
493505.0,"FDA Site Shows Orphan Drug Designation Update For FibroGen's Treatment For Pancreatic Cancer, Pamrevlumab",2017-06-21 07:40:00-04:00,FGEN,negative
493506.0,"FibroGen Reports Q1 EPS $(0.52) vs $(0.49) Est., Sales $26.891M vs $28.14M Est.",2017-05-09 17:10:00-04:00,FGEN,neutral
493507.0,FibroGen Prices Follow-On Offering Of 5.22M Shares At $22.95/Share,2017-04-06 07:03:00-04:00,FGEN,positive
493508.0,FibroGen Reports China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat,2017-03-31 07:09:00-04:00,FGEN,positive
493509.0,"UPDATE: FibroGen Says 'Findings are Consistent with China Phase 3 Trials Results, and Support China NDA Submission'",2017-03-30 07:08:00-04:00,FGEN,positive
493510.0,FibroGen Reports Results from 2 China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease,2017-03-30 07:08:00-04:00,FGEN,neutral
493511.0,"Fibrogen Reports FY16 EPS $(0.98) vs $(1.42) in Same Qtr. Last Year, Sales $179.577M",2017-03-01 16:24:00-05:00,FGEN,neutral
493512.0,Filing form Fibrogen Shows Registration for Mixed Securities Shelf Offering,2017-03-01 16:21:00-05:00,FGEN,positive
493513.0,"FibroGen Reports Publication of FG-3019 Data in Pancreatic Cancer Which Showed Safety, Improved Survival Outcomes in Combo with Chemo",2017-02-03 11:07:00-05:00,FGEN,positive
493514.0,20 Biggest Mid-Day Losers For Monday,2017-01-30 12:52:00-05:00,FGEN,negative
493515.0,25 Stocks Moving In Monday's Pre-Market Session,2017-01-30 08:28:00-05:00,FGEN,neutral
493516.0,FibroGen Reports FG-4592 Met Primary Endpoins in 2 Phase 3 Anemia Studies in China,2017-01-30 07:03:00-05:00,FGEN,neutral
493517.0,7 Biotech Catalysts Remaining In January,2017-01-13 14:08:00-05:00,FGEN,neutral
493518.0,"Fibrogen Reports Q3 EPS $(0.38) vs $(0.60) Est., $(0.74) in Same Qtr. Last Year",2016-11-08 16:05:00-05:00,FGEN,neutral
493519.0,10 Stocks Which Rallied Three Days On Increasing Volume,2016-09-19 09:26:00-04:00,FGEN,neutral
493520.0,"After-Hours Gainers Aug. 8, 2016: HIIQ Up 36%, REN 20%, CCXI 14.4%, FH 14.3%, FGEN 10.4%, AMPH 9.4%, CSLT 8.9%, NVRO 8.7%, ENDP 7.5%",2016-08-08 18:58:00-04:00,FGEN,neutral
493521.0,"FibroGen Reports Q2 EPS $0.39 vs. Est. $0.36, Rev. $89.28M vs. Est. $78.5M",2016-08-08 16:41:00-04:00,FGEN,neutral
493522.0,FibroGen Receives $62M License Payment from AstraZeneca,2016-07-08 04:34:00-04:00,FGEN,neutral
493523.0,FibroGen Announces $10M Milestone Payment,2016-06-09 07:01:00-04:00,FGEN,neutral
493524.0,"FibroGen Reports Q1 EPS $(0.45) Vs Est $(0.56), Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data",2016-05-09 16:04:00-04:00,FGEN,neutral
493525.0,FibroGen Announces Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis,2016-04-21 04:08:00-04:00,FGEN,positive
493526.0,FibroGen Offers Phase 2 Results Supporting Potential FG-3019 to Treat Patients with Idiopathic Pulmonary Fibrosis,2016-03-11 08:05:00-05:00,FGEN,positive
493527.0,Fibrogen Gains On Strong Phase 2 Data,2016-02-16 13:02:00-05:00,FGEN,positive
493528.0,UPDATE: Fibrogen Says Roxadustat Well Tolerated in Study Population;Treatment-Emergent Adverse Events Reported in 63% of All Patients in Safety Population,2016-02-16 07:23:00-05:00,FGEN,positive
493529.0,FibroGen Published Data Shows Roxadustat Ability To Maintain Hemoglobin Levels In Patients With Chronic Kidney Diseaase,2016-02-16 07:21:00-05:00,FGEN,positive
493530.0,Benzinga's Top Upgrades,2016-02-11 08:51:00-05:00,FGEN,positive
493531.0,"Credit Suisse Upgrades FibroGen to Outperform, Raises PT to $40.00",2016-02-11 06:45:00-05:00,FGEN,positive
493532.0,"Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks",2016-01-21 12:16:00-05:00,FGEN,positive
493533.0,"Credit Suisse Initiates Coverage on FibroGen at Neutral, Announces $29.00 PT",2016-01-20 16:45:00-05:00,FGEN,positive
493534.0,"Citigroup Initiates Coverage on FibroGen at Buy, Announces $40.00 PT",2015-12-04 07:41:00-05:00,FGEN,neutral
493535.0,"FibroGen Reports Q3 EPS ($0.74) vs. Est. ($0.59), Rev. $19.538M vs. Est. $31.94M",2015-11-12 16:04:00-05:00,FGEN,neutral
493536.0,"Willdan Group Reports Q2 EPS $0.20 vs Est $0.25, Sales $36.8M Vs Est $35.60M",2015-08-13 16:27:00-04:00,FGEN,neutral
493537.0,"FibroGen Reports Q2 EPS $0.83 Vs Est $0.73, Sales $120.6M Vs Est $111.75M",2015-08-13 16:26:00-04:00,FGEN,neutral
493538.0,"Why Akebia Therapeutics Is Worth $10 Per Share, But Needs More Visibility",2015-08-13 08:35:00-04:00,FGEN,positive
493539.0,ARIAD Reports First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib),2015-08-10 07:36:00-04:00,FGEN,neutral
493540.0,Benzinga's Top Initiations,2015-07-29 09:44:00-04:00,FGEN,positive
493541.0,"Citigroup Initiates Coverage on FibroGen at Buy, Announces $37.00 PT",2015-07-29 07:53:00-04:00,FGEN,neutral
493542.0,FibroGen Receives FDA Clearance to Proceed With Clinical Study of FG-3019 in Duchenne Muscular Dystrophy,2015-07-27 16:06:00-04:00,FGEN,neutral
493543.0,"Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs",2015-07-20 07:56:00-04:00,FGEN,neutral
493544.0,FibroGen Announces $120M Contingent License Payment from AstraZeneca,2015-06-29 16:06:00-04:00,FGEN,neutral
493545.0,Netflix Goes 7-For-1; Vanda Pharma And FibroGen Lead Tuesday's After-Hours Movers,2015-06-23 17:32:00-04:00,FGEN,neutral
493546.0,Morning Market Gainers,2015-06-22 09:43:00-04:00,FGEN,neutral
493547.0,Benzinga's Top #PreMarket Gainers,2015-06-22 08:14:00-04:00,FGEN,positive
493548.0,"FibroGen Reports Q1 Loss $0.78 Vs Est Loss $0.52 May Not Compare, Sales $16.3M",2015-05-12 07:14:00-04:00,FGEN,negative
493549.0,"FibroGen Reports Q1 EPS $(0.78) vs. Est. $(0.52), Rev. $16.29M vs. Est. $34M; Estimates May Not Comapre",2015-05-12 07:05:00-04:00,FGEN,neutral
493550.0,FibroGen Reports Q4 EPS $(1.01) vs. Est. $(0.90),2015-03-26 16:03:00-04:00,FGEN,neutral
493551.0,"Goldman Sachs Downgrades FibroGen to Neutral, Maintains $32.00 PT",2015-01-09 06:44:00-05:00,FGEN,neutral
493552.0,Stocks Hitting 52-Week Highs,2015-01-06 10:23:00-05:00,FGEN,neutral
493553.0,Stocks Hitting 52-Week Highs,2014-12-17 10:14:00-05:00,FGEN,neutral
493554.0,Fibronet Initiated Buy At Stifel With A Price Target Of $39.00,2014-12-09 07:02:00-05:00,FGEN,neutral
493555.0,Fibronet Initiated Outperform At RBC Capital With A Price Target Of $38.00,2014-12-09 06:00:00-05:00,FGEN,neutral
493556.0,"Shares of FibroGen Open for Trade at $23/Share, IPO Priced at $18",2014-11-14 10:43:00-05:00,FGEN,positive
493557.0,FibroGen Shares Remain in Pre-Launch Status Pending Added Price Discovery,2014-11-14 10:32:00-05:00,FGEN,positive
493558.0,Expected IPOs For November 14,2014-11-14 08:57:00-05:00,FGEN,neutral
493559.0,"US Stock Futures Flat Ahead Of Retail Sales, Consumer Sentiment Data",2014-11-14 07:07:00-05:00,FGEN,neutral
493560.0,FibroGen Prices 8.1M Share IPO @$18.00/Share,2014-11-14 05:01:00-05:00,FGEN,positive
